.Pharmacolibrary.Drugs.R_RespiratorySystem.R03B_OtherDrugsForObstructiveAirwayDiseasesInhalants.R03BA07_Mometasone.Mometasone .Pharmacolibrary.Drugs.R_RespiratorySystem.R03B_OtherDrugsForObstructiveAirwayDiseasesInhalants.R03BA07_Mometasone.Mometasone| name: | Mometasone |
| ATC code: | R03BA07 | route: | inhalation |
| n-compartments | 1 |
Mometasone is a potent synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It is primarily used as a topical agent for the treatment of skin disorders, as a nasal spray for allergic rhinitis, and as an inhaled agent for asthma. It is approved for use in many countries.
Estimated pharmacokinetic parameters for inhaled mometasone furoate in healthy adults due to absence of detailed published pharmacokinetic data specific to this ATC classification (R03BA07, inhaled route).
Bartels, C, et al., & Vaidya, S (2021). Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler. European journal of drug metabolism and pharmacokinetics 46(4) 487–504. DOI:10.1007/s13318-021-00689-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/34024035
Inoue, S, et al., & Furihata, K (2021). Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects. BMC pulmonary medicine 21(1) 18–None. DOI:10.1186/s12890-020-01382-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33413291
Zeidler, M, et al., & Tashkin, DP (2010). Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma. Current medical research and opinion 26(6) 1295–1305. DOI:10.1185/03007991003701152 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20370376